ArticleAlcohol, clinical & experimental research2025
Subjective responses to simultaneous alcohol and cannabis use relative to alcohol-only use and cannabis-only use: An ecological momentary assessment investigation.
Article in Alcohol, clinical & experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Influence of cannabis potency on mental health outcomes among adolescents and young adults: scoping review.BJPsych open · 2026Review
- Subjective responses to simultaneous alcohol and cannabis use relative to alcohol-only use and cannabis-only use: An ecological momentary assessment investigation.Alcohol, clinical & experimental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundFew studies have examined subjective responses to simultaneous alcohol and cannabis use in naturalistic settings. The current study used ecological momentary assessment (EMA) to compare subjective responses between simultaneous use and both alcohol-only use and cannabis-only use sessions, while also examining the moderating role of quantities of alcohol and cannabis consumed at both the session and person levels.
methodsYoung adults (N = 149, 59.73% women) reporting recent simultaneous use completed three 21-day EMA bursts, spaced 6 months apart. Participants completed a survey each time they initiated a new session of alcohol or cannabis use, along with two hourly follow-up surveys. Surveys assessed alcohol use (quantities), cannabis use (quantities, forms of cannabis), and current acute subjective responses.
resultsAt the session level, simultaneous use (vs. alcohol-only use) was associated with greater peak sedation and intoxication, with the latter association strengthened during sessions involving relatively lighter drinking. Simultaneous use sessions also involved greater peak liking ratings relative to alcohol-only use sessions, though only among participants who reported relatively lower average alcohol consumption. In addition, relative to cannabis-only use sessions, simultaneous use sessions were associated with greater peak energized and liking ratings, with the former association strengthened during sessions involving relatively heavier cannabis concentrate use. Simultaneous use sessions also involved lower peak sedated and anxious ratings relative to cannabis-only use sessions, though only among participants who reported relatively lighter average cannabis consumption.
conclusionsOverall, simultaneous use was experienced as more impairing (i.e., greater intoxication and sedation) than alcohol-only use and as more reinforcing (i.e., greater stimulation and liking) than cannabis-only use. Some differences in subjective responses between simultaneous use and single-substance use sessions depended on session-level or person-level consumption amounts, which may inform tailored interventions for simultaneous use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.